IMNM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMNM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Immunome's other current assets for the quarter that ended in Dec. 2023 was $2.26 Mil.
Immunome's quarterly other current assets declined from Jun. 2023 ($0.90 Mil) to Sep. 2023 ($0.77 Mil) but then increased from Sep. 2023 ($0.77 Mil) to Dec. 2023 ($2.26Mil).
Immunome's annual other current assets declined from Dec. 2021 ($3.10 Mil) to Dec. 2022 ($1.48 Mil) increased from Dec. 2022 ($1.48 Mil) to Dec. 2023 ($2.26 Mil).
The historical data trend for Immunome's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunome Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Other Current Assets | Get a 7-Day Free Trial | 0.58 | 2.28 | 3.10 | 1.48 | 2.26 |
Immunome Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Other Current Assets | Get a 7-Day Free Trial | 1.48 | 1.29 | 0.90 | 0.77 | 2.26 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of Immunome's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Jean Jacques Bienaime | director | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Robert Lechleider | officer: Chief Medical Officer | C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341 |
Max Rosett | officer: SVP Operations | C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906 |
Clay B Siegall | director, officer: President and CEO | 21823 30TH DR SE, BOTHELL WA 98021 |
Jack Higgins | officer: Chief Scientific Officer | C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906 |
Isaac Barchas | director, other: See remarks | 1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201 |
Bruce Turner | officer: Chief Strategy Officer | C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906 |
James P Boylan | director | C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025 |
Matthew K Robinson | officer: Chief Technology Officer | C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341 |
Michael Rapp | director, 10 percent owner | 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019 |
Franklyn G Prendergast | director | |
Michael Lefenfeld | director | IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341 |
Purnanand D Sarma | director, officer: President and CEO | IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341 |
John L Lamattina | director | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Philip Wagenheim | director | 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By Business Wire • 08-09-2023
By Business Wire Business Wire • 05-23-2023
By Business Wire • 10-19-2023
By Business Wire Business Wire • 05-05-2023
By Business Wire Business Wire • 08-23-2022
By PRNewswire • 06-29-2023
By Business Wire • 11-10-2023
By Business Wire • 06-29-2023
By Business Wire • 11-08-2023
By Business Wire Business Wire • 08-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.